Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants

  title={Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants},
  author={Xin Zhao and Anqi Zheng and Dedong Li and Rong Zhang and Huan Sun and Qihui Wang and George F Gao and Pengcheng Han and Lianpan Dai},
  journal={The Lancet. Microbe},
  pages={e494 - e494}
Covid‐19 vaccines and variants of concern: A review
A review describes the most relevant mutations in the SARS‐CoV‐2 spike protein, discusses VE against VOCs, presents rare adverse events after Covid‐19 vaccination and introduces some promising Covid-19 vaccine candidates.
Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescents
  • Xin Zhao, Dedong Li, +9 authors George Fu Gao
  • 2021
Omicron variant continues to spread all over the world. There are lots of scientific questions remaining to be answered for such a devastating variant. There are a dozen of vaccines already in
Vaccines against COVID-19 – Catching the Rays of Hope
This review aims to elucidate the status of vaccine candidates in advanced trials along with the vaccines, which have been granted emergency approvals, and their probability of efficacy against newer variants of the virus.


BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
The susceptibility of these newly emerged variants to BNT162b2 vaccine-elicited neutralization supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic across geographies.
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
The results suggest that the deployment of RBD-vaccines, through a third-dose boost, may be ideal for combating SARS-CoV-2 variants when necessary, especially for those carrying mutations that disrupt the NTD supersite.
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS
A dimeric form of MERS-CoV RBD is described that overcomes limited immunogenicity and significantly increased neutralizing antibody (NAb) titers compared to conventional monomeric form and protected mice against MSPV infection.
Viral targets for vaccines against COVID-19
As the world races to develop vaccines against SARS-CoV-2, Dai and Gao highlight which viral targets are best to include in a vaccine and how this impacts the induced immune response and the safety and efficacy of a vaccine.